Health & Fitness
0

A partnership between Bristol Myers Squibb and BeiGene on the chemotherapy Abraxane in China has quickly deteriorated since a manufacturing-related ...

0

Takeda is investing more in cell and gene therapy through new deals with Poseida Therapeutics and Immusoft targeting liver and neurometabolic disorders, ...

0

Merck & Co. is adding yet another immuno-oncology first under Keytruda’s belt. But the breadth of the win comes out less than ideal. The FDA has backed ...

0

Millions of people who received the Pfizer COVID-19 vaccine have been eligible to get a third booster dose for weeks, but those who received the other ...

0

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, ...

0

Amid its push to grow around the globe in oncology, rare diseases and neuroscience, Ipsen has poached a Novartis veteran to head up its international ...

0

Takeda's pipeline has taken a hit as the company reported a safety signal from a midstage narcolepsy program. The Japanese pharma doubled down on gene ...

0

Neurocrine Biosciences has turned to the arts before to raise mental health awareness, and the latest iteration of its "Monumental Moments" campaign does it ...

0

Even after the global Zantac recalls of 2019 and 2020 and the associated controversy, the courtroom saga over the medicine's risk is just getting started. ...

0

Despite a recent FDA label restriction, AbbVie is still churning out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor’s ...

0

With Democrats in Washington debating the specifics of the president's infrastructure program, the pharmaceutical industry may be able to squeak out a ...

0

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant ...

You’re Welcome King | Amazon Affiliate Store
Logo
Reset Password